13F reference period
Q2 2026
Security Snapshot
Atea Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (AVIR) Institutional Ownership
CUSIP: 04683R106
13F Institutional Holders and Ownership History from Q4 2020 to Q3 2026
Institutions Reporting
123
Shares (Excl. Options)
59.43M
Full value: 59,434,443 · shares · 30 Jun 2026Price
$4.65
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- AVIR on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 59,434,443
- Total 13F value
- $276,412,137
- Portfolio coverage rank
- 0%
- Share change
- -583,235
- Value change
- -$3,778,264
- Number of holders
- 123
- Shares outstanding
- 80,245,000
- SEC-reported price per share
- $5.21
- Insider filing price
- $5.21
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- AVIR - Atea Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 04683R106.
- 123 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 127 to 123 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$322.77M
Full value: $322,768,077 · USD · 31 Mar 2026.$276.41M
Full value: $276,412,137 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 123 institutions filings for Q2 2026.
Security key
04683R106
13F reference period
Q2 2026
13F holders
123
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
AVIR full holder history
Atea Pharmaceuticals, Inc. SEC filings
Atea Pharmaceuticals, Inc. company facts
Atea Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 04683R106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
AVIR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +28% | $68,238,907 | +$16,302,575 | 11,950,772 | +31% | FMR LLC | 31 Mar 2026 |
| Sommadossi Jean-Pierre | 10% | $26,185,536 | 8,876,453 | Jean-Pierre Sommadossi | 31 Mar 2025 | |||
| BML Investment Partners, L.P. | 9.9% | +16% | $27,881,700 | +$2,119,466 | 7,810,000 | +8.2% | Leonard Braden Michael | 31 Dec 2025 |
| BlackRock, Inc. | 7.1% | $17,942,932 | 6,082,350 | BlackRock, Inc. | 31 Mar 2025 | |||
| TANG CAPITAL MANAGEMENT LLC | 6% | $25,084,106 | 4,814,700 | TANG CAPITAL MANAGEMENT, LLC | 06 Oct 2026 | |||
| Radoff Bradley Louis | 4% | +10% | $9,971,295 | +$811,250 | 3,380,100 | +8.9% | Radoff Bradley Louis | 16 Apr 2025 |
| EcoR1 Capital, LLC | 4% | $9,857,876 | 3,341,653 | EcoR1 Capital, LLC | 31 Dec 2024 |
As of 30 Jun 2026,
123
institutional investors reported holding
shares of
Atea Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (AVIR).
This represents
74%
of the company’s total
outstanding shares.
59.43M
Full value: 59,434,443 · shares · 30 Jun 202680.25M
Full value: 80,245,000 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
68%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 12,004,064 | +0.45% | 0% | $55,818,898 |
| BlackRock, Inc. | 11% | 8,720,077 | +3.4% | 0% | $40,548,360 |
| BML Capital Management, LLC | 8.7% | 6,952,330 | -1.5% | 18% | $32,328,335 |
| TANG CAPITAL MANAGEMENT LLC | 6% | 4,814,700 | 0% | 1% | $22,388,355 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 2,964,862 | -8.7% | 0% | $13,786,608 |
| Bain Capital Life Sciences Investors, LLC | 2.6% | 2,075,639 | -12% | 0.57% | $9,651,721 |
| ACADIAN ASSET MANAGEMENT LLC | 2.5% | 2,035,192 | +29% | 0.01% | $9,455,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 1,958,435 | +12% | 0% | $9,108,898 |
| STATE STREET CORP | 2.1% | 1,652,399 | -2.5% | 0% | $7,683,655 |
| TWO SIGMA INVESTMENTS, LP | 1.9% | 1,506,697 | -19% | 0.01% | $7,006,141 |
| DIMENSIONAL FUND ADVISORS LP | 1.6% | 1,299,515 | +3.5% | 0% | $6,042,497 |
| RENAISSANCE TECHNOLOGIES LLC | 1.4% | 1,131,200 | -3% | 0.01% | $5,260,080 |
| Rosalind Advisors, Inc. | 1.3% | 1,070,550 | -8.6% | 1.9% | $4,978,058 |
| JPMORGAN CHASE & CO | 1.2% | 945,918 | +0.61% | 0% | $4,360,682 |
| NORTHERN TRUST CORP | 0.94% | 755,239 | +29% | 0% | $3,511,862 |
| MORGAN STANLEY | 0.9% | 719,513 | -1.6% | 0% | $3,345,735 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.79% | 630,185 | +13% | 0% | $2,930,360 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.76% | 610,607 | +2.3% | 0% | $2,839,323 |
| GOLDMAN SACHS GROUP INC | 0.66% | 530,856 | -9.8% | 0% | $2,468,480 |
| VANGUARD FIDUCIARY TRUST CO | 0.59% | 469,801 | -3.1% | 0% | $2,184,575 |
| CM Management, LLC | 0.44% | 355,000 | 0% | 1% | $1,650,750 |
| BARCLAYS PLC | 0.43% | 348,653 | +117% | 0% | $1,621,239 |
| D. E. Shaw & Co., Inc. | 0.43% | 345,186 | -9% | 0% | $1,605,115 |
| BANQUE PICTET & CIE SA | 0.43% | 345,077 | 0% | 0.02% | $1,604,608 |
| MILLENNIUM MANAGEMENT LLC | 0.38% | 304,611 | -13% | 0% | $1,416,441 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Headline period
Q2 2026
Rows shown
1-24 of 24
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 856,971 | $4,463,712 | +$473,599 | $5.21 | 26 |
| 2026 Q2 | 59,434,443 | $276,412,137 | -$3,778,264 | $4.65 | 123 |
| 2026 Q1 | 60,096,375 | $322,768,077 | +$18,119,687 | $5.38 | 127 |
| 2025 Q4 | 57,001,968 | $203,464,380 | +$14,036,645 | $3.57 | 111 |
| 2025 Q3 | 53,140,830 | $154,099,223 | +$874,820 | $2.90 | 112 |
| 2025 Q2 | 52,688,325 | $189,687,193 | -$496,611 | $3.60 | 105 |
| 2025 Q1 | 52,943,893 | $158,295,789 | -$11,408,006 | $2.99 | 102 |
| 2024 Q4 | 56,328,149 | $188,651,399 | -$6,772,701 | $3.35 | 103 |
| 2024 Q3 | 57,907,511 | $193,998,567 | +$4,533,749 | $3.35 | 105 |
| 2024 Q2 | 56,687,549 | $187,637,646 | +$7,123,002 | $3.31 | 101 |
| 2024 Q1 | 54,332,807 | $219,504,800 | -$1,664,806 | $4.04 | 112 |
| 2023 Q4 | 55,088,379 | $168,248,591 | -$1,691,841 | $3.05 | 106 |
| 2023 Q3 | 56,849,245 | $170,555,234 | -$2,209,314 | $3.00 | 117 |
| 2023 Q2 | 57,041,241 | $213,289,848 | +$971,494 | $3.74 | 131 |
| 2023 Q1 | 56,778,720 | $190,176,002 | -$5,878,803 | $3.35 | 128 |
| 2022 Q4 | 57,878,556 | $278,395,526 | -$5,016,357 | $4.81 | 130 |
| 2022 Q3 | 57,466,718 | $326,999,436 | -$1,731,457 | $5.69 | 115 |
| 2022 Q2 | 57,566,762 | $408,727,109 | +$19,469,875 | $7.10 | 122 |
| 2022 Q1 | 54,946,542 | $396,539,427 | +$6,369,699 | $7.22 | 121 |
| 2021 Q4 | 53,581,427 | $478,985,081 | -$368,375,568 | $8.94 | 134 |
| 2021 Q3 | 56,840,788 | $1,992,582,650 | -$21,707,203 | $35.06 | 137 |
| 2021 Q2 | 58,896,806 | $1,265,508,812 | +$160,923,836 | $21.48 | 100 |
| 2021 Q1 | 47,389,412 | $2,914,493,173 | +$30,510,569 | $61.75 | 78 |
| 2020 Q4 | 49,910,976 | $2,070,766,859 | +$1,819,869,860 | $41.78 | 69 |